Human Serum Albumin Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Human Serum Albumin Market Size Forecast: How Large Could The Market Become By 2030?
The human serum albumin market has seen notable expansion over the past few years. Projections indicate it will increase from $5.79 billion in 2025 to $6.21 billion in 2026, driven by a compound annual growth rate of 7.3%. During the historic period, this growth was fueled by the restricted supply of recombinant HSA, a heavy dependence on plasma-derived HSA, rising demand from hospitals and clinical settings, broader utilization in diagnostic and therapeutic applications, and the uptake of standard injection solutions.
The human serum albumin market is projected to experience robust expansion over the coming years, with its value anticipated to reach $8.16 billion by 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This forecasted growth is fueled by several key factors, including the advancement of recombinant HSA derived from yeast, bacteria, and plants; a heightened demand for formulations free of fatty acids; the broadening of applications in drug delivery and nutritional enhancement; increased funding for research laboratories; and expanded procurement activities in hospitals and blood banks. Among the predominant trends shaping the market during this period are a growing preference for both plasma-derived and recombinant human serum albumin, an uptick in HSA utilization within volume expanders and drug delivery mechanisms, a greater reliance on lyophilized powders and injectable solutions, an expansion of its use across hospital and research laboratory settings, and a concentrated effort on developing specialty and fatty acid-free HSA preparations.
Download A Free Sample Report For Comprehensive Market Insights:
Human Serum Albumin Market Demand Drivers: What Is Fueling Industry Growth?
The rising incidence of liver disorders is anticipated to drive expansion in the human serum albumin market in the coming period. Liver diseases encompass a range of conditions that compromise hepatic function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. This uptick in liver ailments stems from the growing prevalence of obesity, where excess abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), resulting in fat buildup, inflammation, and the potential for liver failure. Human serum albumin aids in managing liver disease by restoring blood volume, alleviating fluid retention, protecting renal function, and enhancing outcomes in complications like ascites and hepatorenal syndrome. As an example, a report from December 2024 by the Office for Health Improvement and Disparities, a UK government agency, indicated that premature deaths due to alcoholic liver disease rose by 3.6% in 2023, totaling 5,984 cases compared to 5,776 in 2022. Consequently, the growing prevalence of liver diseases is fueling the growth of the human serum albumin market.
Human Serum Albumin Market Segmentation And Category Breakdown
The human serum albumin market covered in this report is segmented –
1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks
Subsegments:
1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin
2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin
Human Serum Albumin Market Innovation Trends: Which Developments Are Transforming The Industry?
Leading companies in the human serum albumin market are concentrating on developing advanced solutions, including animal-free recombinant excipients, aimed at improving product safety, scalability, and adherence to regulatory standards in biomanufacturing. An animal-free recombinant excipient is a biologically engineered inactive substance produced using recombinant DNA technology that contains no components derived from animals or humans, providing high purity and safety in pharmaceutical and biomanufacturing settings. For example, in April 2025, InVitri Inc., a U.S.-based company specializing in animal-free, recombinant proteins and excipients, introduced Optibumin 25, the first recombinant 25% human serum albumin intended for closed-system biomanufacturing. This product is specifically engineered for closed-system processes, optimized for downstream processing, formulation, and cryopreservation workflows, and is offered in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures high purity, consistency, and lower contamination risks. Being GMP-ready and scalable to commercial production levels, it delivers a stable, sterile solution that integrates smoothly into applications like viral vector production, stem cell preservation, vaccine formulation, and more.
Human Serum Albumin Market Competitive Analysis Of Major Industry Participants
Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.
Access The Complete Human Serum Albumin Market Report:
Human Serum Albumin Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
